Results 111 to 120 of about 455 (134)

Safety and tolerability of immunotherapy using various updosing schedules of a new SCIT product with an optimised allergen/aluminium hydroxide ratio

Allergy: European Journal of Allergy and Clinical Immunology, 2011
To cite this article: Jung K. Safety and tolerability of immunotherapy using various updosing schedules of a new SCIT product with an optimised allergen/aluminium hydroxide ratio. Allergy 2011; 66 (Suppl. 95): 41–43.AbstractAllergen extracts for subcutaneous specific immunotherapy (SCIT) may be adsorbed to aluminium hydroxide for adjuvant effect and ...
exaly   +3 more sources

Initial updosing phase of oral immunotherapy improves quality of life and psychological burden in parents of children with food allergy

Allergy and Asthma Proceedings
Background: Oral immunotherapy (OIT) can impose psychological burdens on patients and their parents due to the necessary preparations and repeated adverse reactions. Objective: To investigate changes in quality of life (QoL) and psychological burden in parents of children receiving OIT for food allergy (FA). Methods: Children aged 3‐13 years with FA
Ahn Kangmo, Kim Sukyung, Jung Minyoung   +2 more
exaly   +3 more sources

Remote oral immunotherapy updosing

Annals of Allergy, Asthma and Immunology
Richard L Wasserman
exaly   +2 more sources

Updosing of bilastine is effective in moderate to severe chronic spontaneous urticaria: A real‐life study

Allergy: European Journal of Allergy and Clinical Immunology, 2018
Markus Magerl, Sabine Altrichter, Tomasz Hawro   +2 more
exaly   +3 more sources

Efficacy and Safety of Omalizumab Updosing in Chronic Urticaria: A Retrospective Study.

Skinmed, 2023
Omalizumab is an effective and safe treatment option with licensed doses in patients with chronic spontaneous urticaria (CSU); however, some patients are not responsive to licensed doses and require updosing. As studies concerning updosing were insufficient, the present study evaluated the effectiveness and safety of omalizumab updosing (300 mg every 2
Fatma Asli, Hapa, Fatma Elif, Yıldırım   +1 more
openaire   +1 more source

Once Daily Sublingual Immunotherapy without Updosing – A New Treatment Schedule

International Archives of Allergy and Immunology, 2006
<i>Background:</i> Treatment regimens with specific immunotherapy include updosing. Due to excellent tolerance of sublingual immunotherapy (SLIT), it was hypothesized that administration of once-daily SLIT could be initiated safely without updosing. The objective was to evaluate tolerability of SLIT administered once daily without updosing.
F, Rodriguez, M, Boquete, M D, Ibáñez, F, de la Torre-Martínez, A I, Tabar   +4 more
openaire   +2 more sources

Bilastine: a new H₁‐antihistamine with an optimal profile for updosing in urticaria

Journal of the European Academy of Dermatology and Venereology, 2017
AbstractThis review set out to examine published papers detailing the efficacy of bilastine in skin models and urticaria to assess whether it meets the optimal profile for updosing in urticaria, that is, strong clinical efficacy and freedom from unwanted side effects, particularly sedation.
M K, Church, L, Labeaga
openaire   +2 more sources

Food Sublingual Immunotherapy: Safety and Simplicity of a Real Food Updosing Protocol

The Journal of Allergy and Clinical Immunology: In Practice
Sublingual immunotherapy (SLIT) using food extracts is safe and effective in desensitizing patients with food allergy, yet not often used in clinical practice.To propose a cost-effective, expedited SLIT protocol using real food.Patients with food allergy aged 5 to 50 years (median, 11 years) initiated food SLIT in a single-clinic setting.
Reed R, Windom, Samantha, Seitz, Jean B, Ly, Neha, Dunn, Jennifer, Fergeson, Hugh H, Windom   +5 more
openaire   +2 more sources

Efficacy and tolerability of the updosing of second‐generation non‐sedating H1 antihistamines in children with chronic spontaneous urticaria

Pediatric Allergy and Immunology, 2020
AbstractBackgroundChronic urticaria (CU), daily wheals or angioedema that lasts more than 6 weeks, is a common skin disease; CU is classified as spontaneous (no specific eliciting factor involved) or inducible (specific eliciting factor involved). Recent EAACI guidelines for management of CSU recommend second‐generation non‐sedating H1 antihistamines ...
Sarti, Lucrezia, Barni, Simona, Giovannini, Mattia, Liccioli, Giulia, Novembre, Elio, Mori, Francesca   +5 more
openaire   +2 more sources

Specific Oral Tolerance Induction With A Weekly Updosing Schedule In Children With Ige Mediated Cow's Milk Allergy

Journal of Allergy and Clinical Immunology, 2009
Abstract ...
PAJNO, Giovanni Bat., L. CAMINITI, S. BARBERI, D. VITA, C. E. BAENA CAGNANI, BARBERIO BARBERIO, Giovanni, RUGGERI, Paolo, G. PASSALACQUA   +7 more
openaire   +3 more sources